◆ TICKERBASEOpen interactive view →
◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

HomeAll stocksC › CORT

Corcept Therapeutics Incorporated (CORT) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · BIOTECHNOLOGY · DATA UPDATED 2026-07-31

Corcept Therapeutics Incorporated (CORT) operates in the BIOTECHNOLOGY industry and is headquartered in Redwood City, United States with about 730 employees. Its market capitalization is roughly $12 billion. In the fiscal year ended 2025-12-31, CORT reported $761M in revenue and $100M in net income.

Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States.

Interactive charts & full statements → Open the CORT valuation workbench →

CORT Revenue & Earnings History — Annual Income Statement

Income statementTTM → 2026-06-302025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-312006-12-31
Total Revenue$831M$761M$675M$482M$402M$366M$354M$306M$251M$159M$81M$50M$27M$10M$3M$0M$0M$0M$0M$0M
Gross Profit$817M$748M$664M$476M$396M$361M$348M$301M$246M$156M$79M$49M$26M$10M$3M$0M$0M$0M$0M$0M
Gross Margin %98.3%98.3%98.4%98.7%98.7%98.6%98.4%98.2%97.9%97.8%97.5%97.3%96.7%98.6%97.2%100.0%100.0%100.0%100.0%
Operating Income (EBIT)$6M$45M$137M$107M$113M$124M$128M$112M$89M$53M$10M($3M)($28M)($41M)($36M)($32M)($27M)($20M)($20M)($12M)($26M)
Operating Margin %0.8%5.9%20.3%22.2%28.0%34.0%36.2%36.4%35.6%33.2%12.5%-6.9%-104.0%-400.7%-1096.8%-69827.6%-9420.6%-2540.5%-8701.4%
Net Income$55M$100M$140M$106M$101M$113M$106M$94M$75M$129M$8M($6M)($31M)($46M)($38M)($32M)($26M)($20M)($20M)($12M)($25M)
Net Margin %6.6%13.1%20.7%22.0%25.2%30.7%30.0%30.7%30.0%81.1%10.0%-12.7%-118.2%-444.2%-1150.5%-69537.9%-9598.6%-2401.0%-8460.2%
EBITDA$23M$68M$163M$126M$116M$128M$130M$114M$90M$53M$10M($3M)($27M)($41M)($36M)($32M)($26M)($20M)($20M)($12M)($26M)
Earnings Per Share (EPS)$0.42$0.83$1.23$0.95$0.87$0.89$0.85$0.77$0.60$1.04$0.07$-0.06$-0.31$-0.46$-0.41$-0.39$-0.38$-0.38$-0.43$-0.34$-1.09
Shares Outstanding (M)118M120M113M112M116M126M124M123M127M125M116M107M101M100M93M83M68M52M47M34M23M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

CORT Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-30
Total Revenue$256M$165M$202M$208M$194M$157M$182M$183M
Gross Profit$252M$162M$200M$203M$191M$155M$179M$180M
Gross Margin %98.4%98.2%98.7%97.8%98.2%98.5%98.4%98.4%
Operating Income (EBIT)$41M($50M)$4M$10M$27M$3M$25M$47M
Operating Margin %16.1%-30.1%2.2%4.9%13.7%2.2%13.9%25.5%
Net Income$42M($31M)$24M$20M$35M$21M$30M$47M
Net Margin %16.4%-18.9%12.0%9.5%18.1%13.1%16.7%25.6%
EBITDA$41M($44M)$10M$16M$32M$10M$32M$53M
Earnings Per Share (EPS)$0.36$-0.30$0.20$0.16$0.29$0.17$0.26$0.41
Shares Outstanding (M)118M104M120M119M120M120M118M114M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

CORT Free Cash Flow History

Cash flowTTM → 2026-06-302025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-312006-12-31
Cash from Operations (CFO)$110M$142M$198M$127M$120M$168M$152M$136M$116M$61M$18M$3M($27M)($37M)($36M)($27M)($22M)($18M)($18M)($11M)($23M)
Capital Expenditures (CapEx)$3M$0M$2M$0M$0M$0M$1M$1M$0M$0M$0M$0M$0M$0M$0M$0M$0M$0M$0M$0M$1M
Free Cash Flow (FCF)$107M$142M$196M$127M$120M$167M$151M$135M$115M$61M$18M$3M($28M)($37M)($36M)($27M)($22M)($18M)($18M)($11M)($25M)
FCF Margin %12.9%18.6%29.0%26.3%29.8%45.8%42.6%44.1%45.9%38.0%22.4%6.2%-103.8%-359.0%-1093.8%-61982.8%-8789.0%-2274.7%-8351.4%
Dividends Paid$24M$14M$22M$7M$0M$0M$0M$0M$0M$0M$0M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

CORT Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-30
Cash from Operations (CFO)$34M($17M)$38M$54M$44M$5M$59M$74M
Capital Expenditures (CapEx)$3M$0M$0M$0M$0M$0M$0M$2M
Free Cash Flow (FCF)$31M($17M)$38M$54M$44M$5M$59M$72M
FCF Margin %12.1%-10.3%19.0%26.2%22.6%3.2%32.5%39.6%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

CORT Balance Sheet History

Balance sheet2026-06-302025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-312006-12-31
Total Assets$889M$837M$841M$622M$583M$424M$572M$412M$312M$221M$69M$52M$35M$63M$99M$40M$25M$25M$20M$18M$10M
Cash & Cash Equivalents$111M$120M$128M$136M$66M$78M$477M$31M$207M$104M$52M$40M$24M$55M$93M$40M$25M$24M$15M$11M$9M
Total Liabilities$183M$189M$161M$115M$82M$48M$48M$41M$36M$30M$27M$33M$38M$42M$37M$5M$4M$2M$3M$3M$4M
Total Debt (Short + Long-Term)$2M$1M$1M$0M$1M$1M$2M$2M$0M$0M$15M$28M$34M$35M$32M$0M$0M$0M$0M$0M$0M
Total Shareholders' Equity$706M$648M$680M$507M$502M$376M$523M$371M$276M$191M$41M$18M($3M)$21M$62M$35M$21M$22M$17M$15M$6M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive CORT viewer.

CORT Metric Deep Dives

Other Companies in BIOTECHNOLOGY

This page in other languages: עברית · Русский · Español · Português · 中文 · العربية · Français · Italiano · 日本語 · Deutsch · فارسی · हिन्दी

← CORPAll “C” companiesCORZ →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.